Genefitletics launches Vascomath to fight cardiovascular diseases

Genefitletics has launched VASCOMATH,a machine learning driven human biology model that measures & quantifies molecular signatures underlying gut & oral microbiome functions to predict onset & progression of cardiovascular diseases. The company asserts that VASCOMATH is the industry’s first prediction model that blends biochemistry & mathematics to elucidate biomarkers for CVD, years before disease manifests.

VASOMATH mathematically integrates with Genefitletics’s Molecular Biology Platform, home to its suite of other prediction & early detection models for metabolic, oral diseases & cancer, to construct & deliver molecular data driven nutritional therapeutics interventions that eliminates early molecular signatures before CVD develops

Sushant Kumar, Founder & CEO-Genefitletics, underscores the importance of oral & gut microbiome in addressing chronic diseases including cardiovascular diseases. With 1/3rd of deaths in India attributed to cardiovascular diseases, he accentuates that there is urgent need to measure the asymptomatic biochemical signatures that manifest decades before blood pressure elevates & cholesterol becomes abnormal.

Kumar also stresses on the role of oral health & regular dental screening in preventing the onset of cardiovascular diseases as the metabolic byproducts of oral microbiome can lead to plaque deposition in arteries & increase risk of cardiovascular diseases.

Genefitletics, a consumer biotech & longevity company founded in 2020, offers PROTEBA, a system biology platform, that collects, processes & analyses molecular & phenotype metadata data & overlays mathematical models to measure changes in biochemistry before disease manifests/at earliest stages & provide disease modifiable therapeutics interventions. It engineers & translates 10 million molecular data points from an individual’s biological sample into 100 plus molecular pathways. This enables the company to mathematically ascertain what nutrients or substrates an individual’s body needs to suppress or stimulate certain functions in order to reinstate cellular homeostasis. The company also offers a separate platform for healthcare practitioners- BIACCESS that enables doctors to access molecular signatures, unidentifiable by current suit of diagnostic tests, empowering them to bring precision in their treatment.

CVD Landing page: http://genefitletics.com/cardiovascular-disease/